Delivery Order SPE2DB20D9331-SPE2DB21FL1T2
- Not listed
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the SPE2DB program administered by the Defense Logistics Agency (DLA), a defense agency. The $2,444.40 firm fixed-price contract is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical medication. This award is part of DMS Pharmaceutical Group's larger indefinite delivery contract with the DLA valued at up to $499,999,999, which allows the agency to issue delivery orders...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, provides the Defense Logistics Agency (DLA) with delivery orders for NARCAN 4 MG NASAL SPRAY 2S medication. The contract, valued at $1,625.76, is a firm fixed-price delivery order with a completion date of June 16, 2022. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of branded and generic prescription...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, provides for the delivery of NARCAN 4 MG NASAL SPRAY 2S to the Defense Logistics Agency (DLA). The award is a firm fixed-price delivery order, with no set-aside designation, valued at $7,333.20. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the issuance of delivery orders for a comprehensive range of...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, provides for the delivery of NARCAN 4 MG NASAL SPRAY 2S to the Defense Logistics Agency (DLA). The contract is a firm fixed-price delivery order valued at $7,333.20, with an ultimate completion date of January 6, 2022. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December 31, 2025. This...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order valued at $4,074.00 under the Defense Logistics Agency's (DLA) SPE2DB program. The contract is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a pharmaceutical product, to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract (IDC). The $1,629.60 firm fixed-price award is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a prescription medication. The IDC allows the DLA to issue delivery orders for a comprehensive portfolio of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications,...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a Firm Fixed Price Delivery Order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide NARCAN 4 mg nasal spray with a potential value of $5,304.96 and a completion date of March 6, 2024. This contract is not designated as a set-aside. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler based in Park Ridge, Illinois that provides a wide range of brand and generic prescription and...
- This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, provides for the delivery of NARCAN 4 MG NASAL SPRAY 2S to the Defense Logistics Agency (DLA). The $1,424.52 firm fixed-price delivery order is not associated with any set-aside designation. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a wide...
- This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The $1,629.60 firm fixed-price contract is to provide 4556894654 - NARCAN 4 MG NASAL SPRAY 2S to the DLA, with an ultimate completion date of April 15, 2022. DMS Pharmaceutical Group has a significant $499,999,999 indefinite delivery contract with the DLA under the SPE2DB program, which allows the...
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB program. The $7,333.20 contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a pharmaceutical product, to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
- SPE2DB20D9331Indefinite Delivery Contract
- SPE2DB20D9331-SPE2DB21FL1T2Delivery Order
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The contract, valued at $4,074.00, is for the supply of NARCAN 4 MG NASAL SPRAY 2S to support the medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of medications and medical consumables to the Department of Defense (DoD) and Department of Veterans Affairs (VA). The contract has a firm fixed-price pricing type and does not have a set-aside designation. This award is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical items to fulfill the recurring medical supply requirements of DoD healthcare facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 8/31/21 |